MP30-13 DIAGNOSTIC PERFORMANCE OF SYSTEMATIC FREEHAND TRANSPERINEAL PROSTATE BIOPSY: COMPARISON OF OUTCOMES TO PBCG NOMOGRAM PREDICTIONS OBSERVED OUTCOMES TO PBCG NOMOGRAM PREDICTIONS

You have accessJournal of UrologyProstate Cancer: Detection & Screening III (MP30)1 Sep 2021MP30-13 DIAGNOSTIC PERFORMANCE OF SYSTEMATIC FREEHAND TRANSPERINEAL PROSTATE BIOPSY: COMPARISON OUTCOMES TO PBCG NOMOGRAM PREDICTIONS OBSERVED Shaan Setia, Jamaal Jackson, Demetri Cendo, Michael Gorin, Matthew Allaway, and Srinivas Vourganti SetiaShaan Setia More articles by this author , JacksonJamaal Jackson CendoDemetri Cendo GorinMichael Gorin AllawayMatthew Allaway VourgantiSrinivas View All Author Informationhttps://doi.org/10.1097/JU.0000000000002027.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We assessed the diagnostic performance freehand systematic transperineal biopsy (fTPb) using Prostate Biopsy Collaborative Group (PBCG) nomogram as a comparator. METHODS: From 1/2012 12/2018, fTPb was performed on consecutive men with clinical suspicion prostate cancer. Patients included in study had no prior diagnosis cancer, PSA between 2.5 20 ng/ml, underwent ≥12 core biopsies. Those who pre-biopsy MRI were considered separately from those without prebiopsy imaging. Biopsies single urologist developed needle guidance device used procedure. Clinical pathological data collected retrospectively. compared observed outcomes predicted utilizing chi-square statistical analysis. RESULTS: Systematic (without MRI) 301 (median age 67, mean 6.9 ng/mL). These median cores. Clinically significant cancer (ISUP 2 or greater) found 33.9% men. In MRI, Nomogram, we difference expected number clinically (96 vs 102; p=0.09). An additional 73 7.8 ng/ml) The addition targets sampling resulted 25 49.3%. Using significantly more than predictions (36 20; p≤0.01). There biopsy-related infectious complications. CONCLUSIONS: technique is promising method sample which provides comparable detection TRUS biopsy. that mpMRI greater when technique. Source Funding: none © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e504-e505 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...